329 related articles for article (PubMed ID: 7689596)
1. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. VI. Suppression of adoptively transferred disease and differential effects of oral vs. intravenous tolerization.
Miller A; Zhang ZJ; Sobel RA; al-Sabbagh A; Weiner HL
J Neuroimmunol; 1993 Jul; 46(1-2):73-82. PubMed ID: 7689596
[TBL] [Abstract][Full Text] [Related]
2. Epitopes of myelin basic protein that trigger TGF-beta release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression.
Miller A; al-Sabbagh A; Santos LM; Das MP; Weiner HL
J Immunol; 1993 Dec; 151(12):7307-15. PubMed ID: 7505026
[TBL] [Abstract][Full Text] [Related]
3. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering.
Miller A; Lider O; Roberts AB; Sporn MB; Weiner HL
Proc Natl Acad Sci U S A; 1992 Jan; 89(1):421-5. PubMed ID: 1370356
[TBL] [Abstract][Full Text] [Related]
4. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. V. Hierarchy of suppression by myelin basic protein from different species.
Miller A; Lider O; al-Sabbagh A; Weiner HL
J Neuroimmunol; 1992 Aug; 39(3):243-50. PubMed ID: 1379607
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of experimental autoimmune encephalomyelitis in Lewis rats by nasal administration of encephalitogenic MBP peptides: synergistic effects of MBP 68-86 and 87-99.
Liu JQ; Bai XF; Shi FD; Xiao BG; Li HL; Levi M; Mustafa M; Wahren B; Link H
Int Immunol; 1998 Aug; 10(8):1139-48. PubMed ID: 9723700
[TBL] [Abstract][Full Text] [Related]
6. Antigen-driven bystander suppression after oral administration of antigens.
Miller A; Lider O; Weiner HL
J Exp Med; 1991 Oct; 174(4):791-8. PubMed ID: 1717632
[TBL] [Abstract][Full Text] [Related]
7. Orally administered myelin basic protein in neonates primes for immune responses and enhances experimental autoimmune encephalomyelitis in adult animals.
Miller A; Lider O; Abramsky O; Weiner HL
Eur J Immunol; 1994 May; 24(5):1026-32. PubMed ID: 7514126
[TBL] [Abstract][Full Text] [Related]
8. Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells.
Chen Y; Inobe J; Kuchroo VK; Baron JL; Janeway CA; Weiner HL
Proc Natl Acad Sci U S A; 1996 Jan; 93(1):388-91. PubMed ID: 8552644
[TBL] [Abstract][Full Text] [Related]
9. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain.
Khoury SJ; Hancock WW; Weiner HL
J Exp Med; 1992 Nov; 176(5):1355-64. PubMed ID: 1383385
[TBL] [Abstract][Full Text] [Related]
10. Antigen-driven peripheral immune tolerance: suppression of experimental autoimmmune encephalomyelitis and collagen-induced arthritis by aerosol administration of myelin basic protein or type II collagen.
al-Sabbagh A; Nelson PA; Akselband Y; Sobel RA; Weiner HL
Cell Immunol; 1996 Jul; 171(1):111-9. PubMed ID: 8660845
[TBL] [Abstract][Full Text] [Related]
11. Effect of timing of intravenous administration of myelin basic protein on the induction of tolerance in experimental allergic encephalomyelitis.
Hilliard B; Ventura ES; Rostami A
Mult Scler; 1999 Feb; 5(1):2-9. PubMed ID: 10096096
[TBL] [Abstract][Full Text] [Related]
12. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. III. Synergistic effect of lipopolysaccharide.
Khoury SJ; Lider O; al-Sabbagh A; Weiner HL
Cell Immunol; 1990 Dec; 131(2):302-10. PubMed ID: 1700738
[TBL] [Abstract][Full Text] [Related]
13. Resistance to experimental autoimmune encephalomyelitis induced by neonatal tolerization to myelin basic protein: clonal elimination vs. regulation of autoaggressive lymphocytes.
Qin YF; Sun DM; Goto M; Meyermann R; Wekerle H
Eur J Immunol; 1989 Feb; 19(2):373-80. PubMed ID: 2467819
[TBL] [Abstract][Full Text] [Related]
14. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. II. Suppression of disease and in vitro immune responses is mediated by antigen-specific CD8+ T lymphocytes.
Lider O; Santos LM; Lee CS; Higgins PJ; Weiner HL
J Immunol; 1989 Feb; 142(3):748-52. PubMed ID: 2464023
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction. III. A role for anergy/deletion.
Tan LJ; Vanderlugt CL; McRae BL; Miller SD
Autoimmunity; 1998; 27(1):13-28. PubMed ID: 9482204
[TBL] [Abstract][Full Text] [Related]
16. Nasal administration of multiple antigens suppresses experimental autoimmune myasthenia gravis, encephalomyelitis and neuritis.
Shi FD; Bai XF; Xiao BG; van der Meide PH; Link H
J Neurol Sci; 1998 Feb; 155(1):1-12. PubMed ID: 9562316
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of suppression of experimental autoimmune encephalomyelitis by intravenous administration of myelin basic protein: role of regulatory spleen cells.
Hilliard BA; Kamoun M; Ventura E; Rostami A
Exp Mol Pathol; 2000 Feb; 68(1):29-37. PubMed ID: 10640452
[TBL] [Abstract][Full Text] [Related]
18. Adoptive transfer of experimental allergic encephalomyelitis: recipient response to myelin basic protein-reactive lymphocytes.
Bouwer HG; Hinrichs DJ
J Neuroimmunol; 1994 Oct; 54(1-2):87-98. PubMed ID: 7523447
[TBL] [Abstract][Full Text] [Related]
19. Treatment of autoimmune disease by oral tolerance to autoantigens.
Whitacre CC; Gienapp IE; Meyer A; Cox KL; Javed N
Clin Immunol Immunopathol; 1996 Sep; 80(3 Pt 2):S31-9. PubMed ID: 8811061
[TBL] [Abstract][Full Text] [Related]
20. Myelin antigen-coupled splenocytes suppress experimental autoimmune encephalomyelitis in Lewis rats through a partially reversible anergy mechanism.
Vandenbark AA; Celnik B; Vainiene M; Miller SD; Offner H
J Immunol; 1995 Dec; 155(12):5861-7. PubMed ID: 7499876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
